What we want to be able to do is invest in new antibiotics in ways that actually encourage appropriate use and sales of those antibiotics, and that really is the challenge here.
Queremos ser capaces de investir en novos antibióticos e tamén en maneiras que promovan o uso e venda adecuados  deses antibióticos, e ese é o auténtico desafío.